Delivering Most-favored-nation Prescription Drug

Listen to the summary

0:00

The U.S. funds a disproportionate amount of global pharmaceutical profits while comprising less than 5% of the world's population.
Drug manufacturers often heavily discount products for foreign markets, compensating for this by charging significantly higher prices in the U.S.
American consumers have been unfairly subsidizing the cost of pharmaceuticals for other countries while facing inflated prices domestically.
The Executive Order aims to grant Americans access to the most-favored-nation pricing for pharmaceuticals, aligning U.S. prices with those of comparably developed nations.
Immediate actions will be taken to combat "global freeloading" by pharmaceutical manufacturers, with a commitment to aggressive measures if compliance with pricing standards is not met.
The Secretary of Commerce and the U.S. Trade Representative are tasked with ensuring foreign practices do not undermine U.S. national security or impose unreasonable costs on American patients.
The Secretary of Health and Human Services will facilitate programs allowing consumers to purchase drugs at the most-favored-nation price.
Within 30 days, the Secretary will communicate pricing targets to pharmaceutical manufacturers; subsequent actions will follow if significant progress isn't achieved.
Potential actions outlined include:
- Implementing a rulemaking plan for most-favored-nation pricing.
- Considering drug importation from low-cost countries if legally justifiable.
- Enforcing against anti-competitive practices as identified in an upcoming report.
- Reviewing pharmaceutical exports that contribute to price discrimination.
- Assessing drug approvals regarding safety and effectiveness.
The order clarifies that it does not alter the authorities of any executive department or agency.
Implementation remains subject to applicable law and funding availability.